Glucagon Like Peptide-1 Receptor Agonists and Osteoarthritis

This editorial highlights the promising role of GLP 1 receptor agonists, particularly semaglutide, in managing knee osteoarthritis (OA) in obese patients. A trial by Bilddal et al. demonstrated that semaglutide led to a 13.7% weight loss and a significant reduction in pain (WOMAC score) with an effect size (Cohen’s d = 0.8) surpassing traditional therapies like NSAIDs. The drug’s benefits may stem from both mechanical stress reduction (via weight loss) and anti-inflammatory effects, as GLP 1 receptors are present in joint tissues. While the trial focused on high BMI patients with severe pain, questions remain about efficacy in non obese individuals and long term structural joint preservation. The findings suggest GLP 1 agonists could revolutionize OA treatment by addressing both obesity and inflammation, though broader clinical validation is needed.

This editorial highlights the promising role of GLP 1 receptor agonists, particularly semaglutide, in managing knee osteoarthritis (OA) in obese patients. A trial by Bilddal et al. demonstrated that semaglutide led to a 13.7% weight loss and a significant reduction in pain (WOMAC score) with an effect size (Cohen’s d = 0.8) surpassing traditional therapies like NSAIDs. The drug’s benefits may stem from both mechanical stress reduction (via weight loss) and anti-inflammatory effects, as GLP 1 receptors are present in joint tissues. While the trial focused on high BMI patients with severe pain, questions remain about efficacy in non obese individuals and long term structural joint preservation. The findings suggest GLP 1 agonists could revolutionize OA treatment by addressing both obesity and inflammation, though broader clinical validation is needed.